Real-time imaging of influenza infection in mice is a promising new method to quickly monitor disease progression and to evaluate whether candidate vaccines and treatments are effective in this animal model, according to National Institutes of Health (NIH) scientists.
Flu (Influenza) News Releases
Few influenza viruses are as widespread and adaptable as avian influenza viruses, and scientists are not entirely sure why.
In a new commentary published online in Emerging Infectious Diseases, two leading influenza experts from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, examine how the evolution of proteins found on the surfaces of flu viruses has impacted their ability to infect migratory birds and poultry and cause avian disease.
WHAT: Scientists have identified three types of vaccine-induced antibodies that can neutralize diverse strains of influenza virus that infect humans. The discovery will help guide development of a universal influenza vaccine, according to investigators at the National Institute of Allergy and Infectious Diseases (NIAID), and the National Human Genome Research Institute (NHGRI), both part of the National Institutes of Health (NIH), and collaborators who conducted the research. The findings appear in the July 21st online edition of Cell.
Researchers have used genetic sequencing to show that the 2009 global H1N1 influenza pandemic began in central Mexico, originating in pigs and spreading to humans. Mexico is not typically considered a source of novel influenza strains. The new findings appear online in the journal eLIFE. They shed light on how the novel virus evolved and stress the need for improved influenza surveillance. The research was supported by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.
New findings describe a novel strategy for predicting how circulating influenza viruses will evolve, an approach that may help scientists create better seasonal influenza vaccines.
Several candidate H7N9 pandemic influenza vaccines made from inactivated viruses have been shown to be safe and to generate an immune response.
An experimental vaccine to protect people against H7N9 avian influenza prompted immune responses in 59 percent of volunteers who received two injections at the lowest dosage tested but only if the vaccine was mixed with adjuvant.